Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in P

Frontline cemiplimab plus chemotherapy improved overall survival and progression-free survival compared with investigator’s choice of chemotherapy for patients with PD-L1–positive non–small cell lung cancer that has metastasized to the brain.

Related Keywords

Copenhagen , Køavn , Denmark , Istinye , Istanbul , Turkey , Alaska , United States , Alaskans , American , , European Lung Cancer Congress , Istinye University Faculty Of Medicine , Istinye University Faculty , Lung Cancer , American Indian , Lung Cancer Congress , Frontline Cemiplimab Plus Chemotherapy , Patients With Pd L1 Positive Non Small Cell Lung Cancer , Empower Lung 1 Trial , Nct03088540 , Saadettin Kılıçkap , D ,